摘要
表皮生长因子受体（epidermal growth factor receptor,EGFR）基因突变状态的检测以及表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）的应用开创了晚期非小细胞肺癌患者个体化分子靶向治疗的新纪元。本文就EGFR的不同突变类型与TKIs临床疗效的关系进行综述,为临床上EGFR突变——尤其是少见EGFR突变类型的晚期非小细胞肺癌患者个体化治疗方案的选择提供理论依据。
The application of epidermal growth factor receptor-tyrosine kinase inhibitors（EGFRTKIs） started a new era of target therapy in patients with advanced non-small cell lung cancer（NSCLC）. This article reviews the efficaty of different generations of EGFR-TKIs for NSCLC patients with various EGFR mutation subtypes,focusing on the uncommon EGFR mutations. The aim of the article is to provide theoretical basis for the personalized treatment of NSCLC patients harboring different subtypes of EGFR mutations,especially the less common ones.
作者
秦康
张传涛
张晓春
QIN Kang;ZHANG Chuan-tao;ZHANG Xiao-chun(The Affiliated Hospilal of Qingdao University,Qingdao 266003,China)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2018年第10期779-789,共11页
China Cancer
关键词
表皮生长因子受体
非小细胞肺癌
酪氨酸激酶抑制剂
epidermal growth factor receptor
non-small cell lung cancer
tyrosine kinase inhibilors
